What's Happening?
AstraZeneca has reported promising results from its EMERALD-3 phase 3 trial, which tested the combination of its PD-L1 inhibitor Imfinzi (durvalumab) with CTLA4 inhibitor Imjudo (tremelimumab) and Eisai's multikinase inhibitor Lenvima (lenvatinib) as a first-line
treatment for unresectable hepatocellular carcinoma (HCC) patients. The study focused on patients eligible for transarterial chemoembolisation (TACE), a minimally invasive treatment for liver cancer. The combination therapy showed a statistically significant improvement in progression-free survival compared to TACE alone, with a trend towards improved overall survival. However, the combination of Imfinzi and Imjudo without Lenvima did not show significant improvement over TACE alone. AstraZeneca plans to share these findings with regulatory authorities.
Why It's Important?
The results from the EMERALD-3 trial could have significant implications for the treatment of liver cancer, particularly for patients with unresectable HCC who are eligible for TACE. The combination therapy offers a potential new systemic treatment option that could delay disease progression and improve survival rates. This development is crucial as most patients undergoing TACE experience disease progression or recurrence within six to ten months. The findings could lead to new treatment protocols and potentially improve outcomes for a substantial number of liver cancer patients. AstraZeneca's ongoing research and potential regulatory approval could further solidify its position in the oncology market.
What's Next?
AstraZeneca is expected to continue its discussions with regulatory authorities regarding the approval of Imfinzi in the frontline setting for earlier-stage HCC. The company is also conducting the EMERALD-2 trial, which is examining Imfinzi with or without bevacizumab as adjuvant therapy for HCC patients at high risk of recurrence. The results of this trial, expected later this year, could provide additional data to support the use of Imfinzi in earlier-stage liver cancer. The outcomes of these trials and subsequent regulatory decisions will be closely watched by the medical community and could influence future treatment guidelines.
